Celgene’s chief operating officer and inflammatory diseases guru Scott Smith has quit the company, in the aftermath of the FDA’s rejection of a key multiple sclerosis pill, and a late-stage
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
